Treatment of feline mammary tumours using chemotherapy, surgery and a COX-2 inhibitor drug (meloxicam): a retrospective study of 23 cases (2002-2007)*.
The efficacy of a treatment combination of a COX-2 inhibitor (meloxicam), chemotherapy and surgery in 23 cats with histologically confirmed mammary gland adenocarcinoma was evaluated. All of the cases underwent an aggressive surgery with concurrent doxorubicin-based chemotherapy. Meloxicam was given orally starting the day after surgery and was continued indefinitely. Serum renal parameters were measured every 3-5 months. Three cats developed azotemia, whereas in four other renal parameters increased but remained within normal limit. The Kaplan-Meier median survival time was 460 days. The Kaplan-Meier median disease free interval was 269 days. The survival times are similar to other studies, not supporting the use of this treatment combination. Prospective studies with a higher number of cases are warranted to investigate the utility of this multimodality protocol for the treatment of feline mammary tumours.
Borrego
J F
JF
CMA Hospital, Nexo group, Valencia, Spain.
Cartagena
J C
JC
Engel
J
J
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002371:Cat Diseases / Q000628:therapy*; D002415:Cats; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use*; D005260:Female; D015674:Mammary Neoplasms, Animal / Q000145:classification / Q000628:therapy*; D000077239:Meloxicam; D012189:Retrospective Studies; D013843:Thiazines / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D052246:Cyclooxygenase 2 Inhibitors; D013843:Thiazines; D013844:Thiazoles; D000077239:Meloxicam